Michael Valentino

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

Breakthrough Products, Inc. develops and sells over-the-counter medications. Its products include medications for head ache, heart burn, allergy attack, ache and pain, and upset stomach in the form of powders. The company was founded by Jordan Eisenberg in 2010 and is headquartered in Denver, CO.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY.

Zoetis Products LLC engaged in the manufacturing of pharmaceutical products. The company was founded in 1975 and was headquartered in Florham Park, NJ.

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE.